CAJ | 학술논문

随着我国精准医学计划的推出，肿瘤的个体化靶向治疗也进入了新阶段，肺癌基因分子生物学研究的不断进展，促进发现了众多的分子靶点。然而如何筛选出适应于靶向治疗的患者，使精准的个体化治疗得以实现成为临床面临的一个挑战。伴随诊断能够很好的评估患者情况，帮助临床决策，从而使患者获益最大并降低副反应发生风险。高通量测序技术的飞速发展及其在液体活检标本上的应用探索，也为研究肿瘤发生发展和寻找潜在治疗靶点提供了更多的思路。（中华检验医学杂志，2015，38：649－652）
수착아국정준의학계화적추출，종류적개체화파향치료야진입료신계단，폐암기인분자생물학연구적불단진전，촉진발현료음다적분자파점。연이여하사선출괄응우파향치료적환자，사정준적개체화치료득이실현성위림상면림적일개도전。반수진단능구흔호적평고환자정황，방조림상결책，종이사환자획익최대병강저부반응발생풍험。고통량측서기술적비속발전급기재액체활검표본상적응용탐색，야위연구종류발생발전화심조잠재치료파점제공료경다적사로。（중화검험의학잡지，2015，38：649－652）
As the precision medicine has been proposed , personalized therapy in cancer steps into a new stage.Since the development of gene molecular biology in lung cancer , numerous molecular targets were discovered.However, selecting patients who will be the most likely to benefit from the therapy is still a great challenge in clinical practice .Companion diagnosis could help evaluate the status of patients , which may provide better suggestions for health care professionals during treatment decision , in order to benefit the patients and decline the side effects risk together .Besides, high-throughput sequencing technics and diverse detection samples has provided a novel direction to understand the tumorigenesis and find more potential gene targets.